Inflammation rapidly recruits mammalian GMP and MDP from bone marrow into regional lymphatics

  1. Juana Serrano-Lopez
  2. Shailaja Hegde
  3. Sachin Kumar
  4. Josefina Serrano
  5. Jing Fang
  6. Ashley M Wellendorf
  7. Paul A Roche
  8. Yamileth Rangel
  9. Leolene J Carrington
  10. Hartmut Geiger
  11. H Leighton Grimes
  12. Sanjiv Luther
  13. Ivan Maillard
  14. Joaquin Sanchez-Garcia
  15. Daniel T Starczynowski
  16. Jose A Cancelas  Is a corresponding author
  1. University of Cincinnati, United States
  2. Hospital Reina Sofia, United States
  3. National Institutes of Health/NCI, United States
  4. Hospital Reina Sofia, Spain
  5. University of Pennsylvania, United States
  6. University of Cincinnati College of Medicine, United States
  7. University of Lausanne, Switzerland

Abstract

Innate immune cellular effectors are actively consumed during systemic inflammation but the systemic traffic and the mechanisms that support their replenishment remain unknown. Here we demonstrate that acute systemic inflammation induces the emergent activation of a previously unrecognized system of rapid migration of granulocyte-macrophage progenitors and committed macrophage-dendritic progenitors, but not other progenitors or stem cells, from bone marrow (BM) to regional lymphatic capillaries. The progenitor traffic to the systemic lymphatic circulation is mediated by Ccl19/Ccr7 and is NFkB independent, Traf6/IkB-kinase/SNAP23 activation dependent, and is responsible for the secretion of pre-stored Ccl19 by a subpopulation of CD205+/CD172a+ conventional dendritic cells type 2 (cDC2) and upregulation of BM myeloid progenitor Ccr7 signaling. Mature myeloid Traf6 signaling is anti-inflammatory and necessary for lymph node (LN) myeloid cell development. This report unveils the existence and the mechanistic basis of a very early direct traffic of myeloid progenitors from BM to lymphatics during inflammation.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Juana Serrano-Lopez

    Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Shailaja Hegde

    Hoxworth Blood Center, University of Cincinnati, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Sachin Kumar

    Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Josefina Serrano

    Hematology, Hospital Reina Sofia, Cordoba, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jing Fang

    Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Ashley M Wellendorf

    Hoxworth Blood Center, University of Cincinnati, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Paul A Roche

    Experimental Immunology Branch, National Institutes of Health/NCI, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Yamileth Rangel

    Hematology, Hospital Reina Sofia, Cordoba, Spain
    Competing interests
    The authors declare that no competing interests exist.
  9. Leolene J Carrington

    Dept. of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7352-3270
  10. Hartmut Geiger

    University of Cincinnati College of Medicine, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5794-5430
  11. H Leighton Grimes

    University of Cincinnati College of Medicine, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Sanjiv Luther

    University of Lausanne, Lausanne, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  13. Ivan Maillard

    Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Joaquin Sanchez-Garcia

    Hematology, Hospital Reina Sofia, Cordoba, Spain
    Competing interests
    The authors declare that no competing interests exist.
  15. Daniel T Starczynowski

    University of Cincinnati College of Medicine, Cincinnati, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Jose A Cancelas

    Hoxworth Blood Center, University of Cincinnati, Cincinnati, United States
    For correspondence
    jose.cancelas@uc.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1291-7233

Funding

National Institutes of Health (GM110628)

  • Jose A Cancelas

National Institutes of Health (DK124115)

  • Jose A Cancelas

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocol #2019-0041 of Cincinnati Children's Hospital.

Human subjects: Lymphadenopathies from patients were obtained through Institutional Review Board-approved protocols of the Hospital Reina Sofia (Cordoba, Spain), donor informed consent and legal tutor approval in the case of patients younger than 18 years old. Specimens were blindly analyzed through adjudication of unique identifiers.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,925
    views
  • 247
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Juana Serrano-Lopez
  2. Shailaja Hegde
  3. Sachin Kumar
  4. Josefina Serrano
  5. Jing Fang
  6. Ashley M Wellendorf
  7. Paul A Roche
  8. Yamileth Rangel
  9. Leolene J Carrington
  10. Hartmut Geiger
  11. H Leighton Grimes
  12. Sanjiv Luther
  13. Ivan Maillard
  14. Joaquin Sanchez-Garcia
  15. Daniel T Starczynowski
  16. Jose A Cancelas
(2021)
Inflammation rapidly recruits mammalian GMP and MDP from bone marrow into regional lymphatics
eLife 10:e66190.
https://doi.org/10.7554/eLife.66190

Share this article

https://doi.org/10.7554/eLife.66190

Further reading

    1. Immunology and Inflammation
    Eugenio Antonio Carrera Silva, Juliana Puyssegur, Andrea Emilse Errasti
    Review Article

    The gut biome, a complex ecosystem of micro- and macro-organisms, plays a crucial role in human health. A disruption in this evolutive balance, particularly during early life, can lead to immune dysregulation and inflammatory disorders. ‘Biome repletion’ has emerged as a potential therapeutic approach, introducing live microbes or helminth-derived products to restore immune balance. While helminth therapy has shown some promise, significant challenges remain in optimizing clinical trials. Factors such as patient genetics, disease status, helminth species, and the optimal timing and dosage of their products or metabolites must be carefully considered to train the immune system effectively. We aim to discuss how helminths and their products induce trained immunity as prospective to treat inflammatory and autoimmune diseases. The molecular repertoire of helminth excretory/secretory products (ESPs), which includes proteins, peptides, lipids, and RNA-carrying extracellular vesicles (EVs), underscores their potential to modulate innate immune cells and hematopoietic stem cell precursors. Mimicking natural delivery mechanisms like synthetic exosomes could revolutionize EV-based therapies and optimizing production and delivery of ESP will be crucial for their translation into clinical applications. By deciphering and harnessing helminth-derived products’ diverse modes of action, we can unleash their full therapeutic potential and pave the way for innovative treatments.

    1. Cell Biology
    2. Immunology and Inflammation
    Mykhailo Vladymyrov, Luca Marchetti ... Britta Engelhardt
    Tools and Resources

    The endothelial blood-brain barrier (BBB) strictly controls immune cell trafficking into the central nervous system (CNS). In neuroinflammatory diseases such as multiple sclerosis, this tight control is, however, disturbed, leading to immune cell infiltration into the CNS. The development of in vitro models of the BBB combined with microfluidic devices has advanced our understanding of the cellular and molecular mechanisms mediating the multistep T-cell extravasation across the BBB. A major bottleneck of these in vitro studies is the absence of a robust and automated pipeline suitable for analyzing and quantifying the sequential interaction steps of different immune cell subsets with the BBB under physiological flow in vitro. Here, we present the under-flow migration tracker (UFMTrack) framework for studying immune cell interactions with endothelial monolayers under physiological flow. We then showcase a pipeline built based on it to study the entire multistep extravasation cascade of immune cells across brain microvascular endothelial cells under physiological flow in vitro. UFMTrack achieves 90% track reconstruction efficiency and allows for scaling due to the reduction of the analysis cost and by eliminating experimenter bias. This allowed for an in-depth analysis of all behavioral regimes involved in the multistep immune cell extravasation cascade. The study summarizes how UFMTrack can be employed to delineate the interactions of CD4+ and CD8+ T cells with the BBB under physiological flow. We also demonstrate its applicability to the other BBB models, showcasing broader applicability of the developed framework to a range of immune cell-endothelial monolayer interaction studies. The UFMTrack framework along with the generated datasets is publicly available in the corresponding repositories.